首页 | 本学科首页   官方微博 | 高级检索  
检索        


Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated,anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase III randomised controlled trial
Institution:1. Department of Medical Oncology, National Cancer Centre/National Clinical Research Centre for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China;2. State Key Laboratory of Molecular Oncology, National Cancer Centre/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China;3. Department of Internal Medicine, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Shenyang, China;4. Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China;5. Department of Medical Oncology, Sun Yat-sen University Cancer Centre, Guangzhou, China;6. Department of Breast Cancer, The Fifth Medical Cent, Chinese PLA General Hospital, Beijing, China;7. Department of Breast Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China;8. Breast Cancer Centre, Henan Cancer Hospital, Zhengzhou, China;9. Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China;10. Department of Medical Oncology, Fudan University Cancer Center, Shanghai, China;11. Department of Medical Oncology, The PLA General Hospital, Beijing, China;12. Department of Medical Oncology, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China;13. Department of Breast Oncology, Tianjin Medical University Cancer Hospital, Tianjin, China;14. Department of Breast Oncology, Peking University Cancer Hospital, Beijing, China;15. Department of Medical Oncology, Nankai University Tianjing People’s Hospital, Tianjing, China;16. Breast Cancer Center, Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China;17. Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China;18. Department of Oncology, Qingdao University Yantai Yuhuangding Hospital, Yantai, China;19. Department of Medical Oncology, Sichuan University West China Hospital, Chengdu, China;20. Department of Oncology, Tongji Medical College Wuhan Union Hospital, Wuhan, China;21. Department of Breast Surgery, Shanghai Jiaotong University Renji Hospital, Shanghai, China;22. Department of Medical Oncology, Nantong Tumor Hospital, Nantong, China;23. Department of Breast Oncology, Hebei Medical University Tumor Hospital, Shijiazhuang, China;24. Department of Medical Oncology, Fujian Medical University Cancer Hospital, Fuzhou, China;25. Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China;26. Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China;27. Department of Breast Surgery, Sichuan Cancer Hospital, Chengdu, China;28. Department of Research and Development, Beijing Biostar Technologies, Beijing, China
Abstract:
Keywords:utidelone  capecitabine  metastatic breast cancer  overall survival  anthracycline- and taxane-refractory
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号